Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.63 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcodeine SCHEMBL120270 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL120271 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL18462800 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL16922132 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL12638889 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL24541888 | 1.00 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL4856570 | 0.99 | MRGPRX2 (0.98) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL6220787 | 0.99 | MRGPRX2 (0.98) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL7593070 | 0.98 | MRGPRX2 (0.96) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Codeine SCHEMBL20703798 | 0.90 | OPRM1 (0.83) | MRGPRX2MAPTOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2633305-B1 | AUTOMATED SYSTEM FOR SAMPLE PREPARATION AND ANALYSIS | THERMO FISHER SCIENTIFIC OY (FI) | 2023-03-01 | — | — | EP | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240210288-A1 | Representative Diagnostics | VENTANA MED SYST INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| US-11959838-B2 | Representative diagnostics | VENTANA MEDICAL SYSTEMS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022174035-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | MRGPRX2 588/4885MAPT 417/4885OPRM1 3535/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | MRGPRX2 588/4885MAPT 417/4885OPRM1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.